Literature DB >> 24920783

PCR-based detection and molecular characterization of shiga toxin-producing Escherichia coli strains in a routine microbiology laboratory over 16 years.

K Haugum1, L T Brandal2, B-A Lindstedt3, A L Wester2, K Bergh4, J E Afset5.   

Abstract

Shiga toxin-producing Escherichia coli (STEC) is a heterogeneous group of bacteria causing disease ranging from asymptomatic carriage and mild infection to hemolytic uremic syndrome (HUS). Here, we describe patients with STEC infection and characterize the STEC strains detected in our laboratory by use of PCR for stx1, stx2, and eae from 1996 through 2011. Patient information was collected from referral forms and from the Norwegian Surveillance System for Communicable Diseases. STEC isolates were characterized with respect to serogroup or serotype, selected potential virulence genes, and multilocus variable-number tandem-repeat analysis (MLVA) genotype. STEC strains were isolated from 138 (1.09%) of 12,651 patients tested. STEC strains of serogroups O26, O103, O121, O145, and O157 were the most frequent. These serogroups, except non-sorbitol-fermenting O157, were also the most frequent among the 11 patients (all ≤5 years old) who developed HUS. Twenty-four STEC strains were classified as being HUS associated based on an epidemiological link to a HUS case, including an MLVA genotype identical to that of the STEC strain. The age of the patient (≤5 years) and the genes eae and stx2a were significantly associated with HUS-associated STEC (P < 0.05 for each parameter), while stx1 was associated with non-HUS-associated STEC (P < 0.05). All of the potential virulence genes analyzed, except ehxA, were significantly more frequent among HUS-associated than non-HUS-associated strains (P < 0.05 for each gene). However, these genes were also present in some non-HUS-associated STEC strains and could therefore not reliably differentiate between HUS-associated and non-HUS-associated STEC strains.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24920783      PMCID: PMC4313131          DOI: 10.1128/JCM.00453-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  46 in total

1.  Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome.

Authors:  Martina Bielaszewska; Alexander W Friedrich; Thomas Aldick; Robin Schürk-Bulgrin; Helge Karch
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

Review 2.  New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome.

Authors:  Helge Karch; Alexander W Friedrich; Angela Gerber; Lothar B Zimmerhackl; M Alexander Schmidt; Martina Bielaszewska
Journal:  Semin Thromb Hemost       Date:  2006-03       Impact factor: 4.180

Review 3.  Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections.

Authors:  H Karch; M Bielaszewska; M Bitzan; H Schmidt
Journal:  Diagn Microbiol Infect Dis       Date:  1999-07       Impact factor: 2.803

Review 4.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Polymerase chain reaction for diagnosis of enterohemorrhagic Escherichia coli infection and hemolytic-uremic syndrome.

Authors:  M J Brian; M Frosolono; B E Murray; A Miranda; E L Lopez; H F Gomez; T G Cleary
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

6.  The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli.

Authors:  Kristine E Johnson; Cheleste M Thorpe; Cynthia L Sears
Journal:  Clin Infect Dis       Date:  2006-11-09       Impact factor: 9.079

7.  Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

Authors:  M A Karmali; B T Steele; M Petric; C Lim
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

8.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

9.  Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome.

Authors:  H Rüssmann; H Schmidt; J Heesemann; A Caprioli; H Karch
Journal:  J Med Microbiol       Date:  1994-05       Impact factor: 2.472

10.  Detection and characterization of the eae gene of Shiga-like toxin-producing Escherichia coli using polymerase chain reaction.

Authors:  V P Gannon; M Rashed; R K King; E J Thomas
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

View more
  11 in total

1.  Assessing the public health risk of Shiga toxin-producing Escherichia coli by use of a rapid diagnostic screening algorithm.

Authors:  Richard F de Boer; Mithila Ferdous; Alewijn Ott; Henk R Scheper; Guido J Wisselink; Max E Heck; John W Rossen; Anna M D Kooistra-Smid
Journal:  J Clin Microbiol       Date:  2015-03-04       Impact factor: 5.948

2.  Molecular profiling of Escherichia coli O157:H7 and non-O157 strains isolated from humans and cattle in Alberta, Canada.

Authors:  Linda Chui; Vincent Li; Patrick Fach; Sabine Delannoy; Katarzyna Malejczyk; Laura Patterson-Fortin; Alan Poon; Robin King; Kimberley Simmonds; Allison N Scott; Mao-Cheng Lee
Journal:  J Clin Microbiol       Date:  2014-12-24       Impact factor: 5.948

3.  Etiological diagnosis of post-diarrheal hemolytic uremic syndrome (HUS): humoral response contribution.

Authors:  Gabriela A Fiorentino; Elizabeth Miliwebsky; María Victoria Ramos; Gisela Zolezzi; Isabel Chinen; Glenda Guzmán; Rubén Nocera; Romina Fernández-Brando; Adriana Santiago; Ramón Exeni; Marina S Palermo
Journal:  Pediatr Nephrol       Date:  2022-07-08       Impact factor: 3.714

4.  Comparative genomics to delineate pathogenic potential in non-O157 Shiga toxin-producing Escherichia coli (STEC) from patients with and without haemolytic uremic syndrome (HUS) in Norway.

Authors:  Kjersti Haugum; Jostein Johansen; Christina Gabrielsen; Lin T Brandal; Kåre Bergh; David W Ussery; Finn Drabløs; Jan Egil Afset
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

5.  Virulence factors of Shiga toxin-producing Escherichia coli and the risk of developing haemolytic uraemic syndrome in Norway, 1992-2013.

Authors:  U Naseer; I Løbersli; M Hindrum; T Bruvik; L T Brandal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-08       Impact factor: 3.267

6.  Virulence Characteristics and Antimicrobial Resistance Profiles of Shiga Toxin-Producing Escherichia coli Isolates from Humans in South Africa: 2006-2013.

Authors:  Musafiri Karama; Beniamino T Cenci-Goga; Mogaugedi Malahlela; Anthony M Smith; Karen H Keddy; Saeed El-Ashram; Lawan M Kabiru; Alan Kalake
Journal:  Toxins (Basel)       Date:  2019-07-19       Impact factor: 4.546

7.  Shiga toxin-producing escherichia coli infections in Norway, 1992-2012: characterization of isolates and identification of risk factors for haemolytic uremic syndrome.

Authors:  Lin T Brandal; Astrid L Wester; Heidi Lange; Inger Løbersli; Bjørn-Arne Lindstedt; Line Vold; Georg Kapperud
Journal:  BMC Infect Dis       Date:  2015-08-11       Impact factor: 3.090

8.  Shiga Toxin-Producing Escherichia coli Infection in Jönköping County, Sweden: Occurrence and Molecular Characteristics in Correlation With Clinical Symptoms and Duration of stx Shedding.

Authors:  Xiangning Bai; Sara Mernelius; Cecilia Jernberg; Ing-Marie Einemo; Stefan Monecke; Ralf Ehricht; Sture Löfgren; Andreas Matussek
Journal:  Front Cell Infect Microbiol       Date:  2018-05-01       Impact factor: 5.293

9.  Twenty-seven years of screening for Shiga toxin-producing Escherichia coli in a university hospital. Brussels, Belgium, 1987-2014.

Authors:  Klara De Rauw; Steve Jacobs; Denis Piérard
Journal:  PLoS One       Date:  2018-07-02       Impact factor: 3.240

10.  Mapping of control measures to prevent secondary transmission of STEC infections in Europe during 2016 and revision of the national guidelines in Norway.

Authors:  L Veneti; H Lange; L Brandal; K Danis; L Vold
Journal:  Epidemiol Infect       Date:  2019-09-09       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.